Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

  • Home
  • /
  • Themis Medicare
Join Channel
Consolidated Standalone

Themis Medicare

₹208.5 0.5 | 0.2%

Market Cap ₹1919 Cr.

Stock P/E 42.4

P/B 5.2

Current Price ₹208.5

Book Value ₹ 39.8

Face Value 1

52W High ₹1700

Dividend Yield 0.24%

52W Low ₹ 131.3

Edit Ratio

Themis Medicare Research see more...

Overview Inc. Year: 1969Industry: Pharmaceuticals & Drugs

Themis Medicare Ltd is a pharmaceutical corporation. The Company is engaged in production of pharmaceuticals and medicinal chemical compounds. The Company focuses on therapeutic areas, consisting of anti-tuberculosis, anti-malarial, cardiology, ache management, anti-infectives, haematinics, fitness and nutrition. The Company's active pharmaceutical substances (APIs) encompass Simvastatin, Ethambutol, Artemether, Artesunate, Arteether and Di Methyl Isosorbide. The Company's formulations encompass authentic products, new drug shipping systems (NDDS), dietary supplements and others. Its original merchandise encompass Emal injection, Sepgard Gel, Sepgard Mouth Gargle and Sepgard Solution. The Company's NDDS consist of Injection Diclofenac Sodium, Gel Diclofenac Diethylamine, Emal Prefilled Injection, Etojet injection and Injection Aceclofenac. The Company offers a number of nutritional supplements, which consist of Gummy Vita (Kids), Gummy Cal (Kids) and Gummy Cal (Adults).

Read More..

Themis Medicare Share Price

New

₹ | |

Volume
Price

Quarterly Price

Quarterly Monthly
Show Value Show %

Peer Comparison

Themis Medicare Quarterly Results

#(Fig in Cr.) Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 107 95 80 94 91 89 80 97 105 83
Other Income 0 4 2 1 2 6 3 1 2 1
Total Income 108 99 82 95 93 95 83 97 107 83
Total Expenditure 84 78 65 74 70 74 70 75 92 74
Operating Profit 24 21 16 21 23 21 13 22 15 9
Interest 2 2 2 2 2 2 3 2 2 3
Depreciation 2 2 2 2 3 3 3 3 3 3
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 19 17 12 16 18 16 8 17 10 3
Provision for Tax 4 5 4 5 5 4 2 4 3 1
Profit After Tax 15 12 8 12 14 12 6 13 7 2
Adjustments 4 0 2 6 4 1 2 6 4 5
Profit After Adjustments 19 12 10 17 18 13 8 18 11 7
Adjusted Earnings Per Share 2.1 1.4 1.1 1.9 1.9 1.4 0.9 2 1.2 0.8

Themis Medicare Profit & Loss

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
Net Sales 174 195 202 232 217 210 184 202 231 395 354 365
Other Income 3 5 13 3 3 3 3 3 4 7 12 7
Total Income 177 200 214 236 220 213 186 205 234 401 366 370
Total Expenditure 157 171 184 194 184 185 181 166 181 299 287 311
Operating Profit 20 29 31 41 36 28 5 39 53 102 79 59
Interest 15 16 15 12 12 12 12 13 13 9 10 10
Depreciation 9 9 11 12 7 7 8 8 9 9 10 12
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0 0 0
Profit Before Tax -4 4 5 17 16 9 -15 18 32 95 73 38
Provision for Tax 2 1 -1 2 2 0 -2 2 6 22 16 10
Profit After Tax -6 3 5 15 15 9 -13 16 26 73 57 28
Adjustments 0 0 1 1 1 3 2 9 9 0 0 17
Profit After Adjustments -6 3 6 16 16 11 -11 25 36 73 57 44
Adjusted Earnings Per Share -0.8 0.3 0.7 1.9 1.8 1.2 -1.2 2.7 3.9 7.9 6.2 4.9

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR -10% 21% 11% 7%
Operating Profit CAGR -23% 27% 23% 15%
PAT CAGR -22% 53% 45% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 35% 67% 49% 42%
ROE Average 18% 20% 12% 10%
ROCE Average 21% 22% 15% 13%

Themis Medicare Balance Sheet

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Shareholder's Funds 52 57 59 74 152 169 158 183 219 287 339
Minority's Interest 0 0 0 0 0 -0 -0 -0 -0 -0 -0
Borrowings 92 77 75 63 12 11 9 12 22 24 28
Other Non-Current Liabilities 8 13 7 7 -5 -5 -7 -4 2 7 7
Total Current Liabilities 120 137 136 130 124 125 147 155 128 124 149
Total Liabilities 272 284 277 275 284 301 307 345 371 442 524
Fixed Assets 124 121 122 117 124 126 123 116 133 144 162
Other Non-Current Assets 24 28 21 24 36 32 34 49 53 70 87
Total Current Assets 124 134 133 133 124 143 150 180 185 228 275
Total Assets 272 284 277 275 284 301 307 345 371 442 524

Themis Medicare Cash Flow

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Opening Cash & Cash Equivalents -67 -38 -35 -40 6 6 4 2 3 19 20
Cash Flow from Operating Activities 4 8 19 26 -2 8 11 0 57 34 16
Cash Flow from Investing Activities -5 -7 -6 -7 -4 -0 -4 -5 -16 -16 -24
Cash Flow from Financing Activities 29 2 -18 -13 5 -9 -10 7 -26 -18 0
Net Cash Inflow / Outflow 29 4 -5 5 -0 -1 -3 2 16 1 -8
Closing Cash & Cash Equivalent -38 -35 -40 -34 6 4 2 3 19 20 13

Themis Medicare Ratios

# Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Earnings Per Share (Rs) -0.78 0.32 0.73 1.91 1.77 1.23 -1.17 2.7 3.89 7.92 6.18
CEPS(Rs) 0.32 1.43 2 3.18 2.46 1.75 -0.55 2.63 3.78 8.95 7.32
DPS(Rs) 0.09 0 0.18 0 0 0 0 0.18 0.43 0.5 0.5
Book NAV/Share(Rs) 6.37 6.69 6.99 8.69 16.64 18.34 17.15 19.87 23.74 31.22 36.88
Core EBITDA Margin(%) 9.6 12.26 8.8 16.17 14.31 11.58 1.24 17.69 21.46 24.24 19.04
EBIT Margin(%) 6.42 9.99 9.33 12.49 12.48 9.73 -1.66 15.3 19.32 26.36 23.17
Pre Tax Margin(%) -2.31 2.03 2.22 7.26 7.24 4.13 -8.09 8.91 13.81 24.14 20.47
PAT Margin (%) -3.61 1.37 2.66 6.45 6.53 4.08 -7.09 7.88 11.37 18.47 16.06
Cash Profit Margin (%) 1.48 6.14 8.29 11.49 9.83 7.58 -2.74 11.98 15.08 20.87 19.02
ROA(%) -2.29 0.97 1.94 5.52 5.29 2.95 -4.29 4.86 7.32 17.93 11.78
ROE(%) -11.5 5 9.4 22.85 13.16 5.42 -8 9.34 13.09 28.84 18.16
ROCE(%) 5.39 9.53 9.45 14.69 12.92 8.52 -1.25 11.81 15.21 31.07 20.59
Receivable days 83.91 66.9 76.05 72.04 77.33 100.75 140.57 158.78 142.49 82.4 126.49
Inventory Days 106.28 112.58 114.91 93.26 86.11 84.49 102.51 97.99 89.48 55.18 66.84
Payable days 269.51 258.51 268.82 243.05 218.14 196.51 203.52 227.3 163.89 87.3 130.58
PER(x) 0 18.15 18.77 18.68 34.83 45.22 0 8.9 7.21 11.78 18.87
Price/Book(x) 0.83 0.87 1.97 4.11 3.7 3.03 1.73 1.21 1.18 2.99 3.16
Dividend Yield(%) 1.71 0 1.31 0 0 0 0 0.73 1.53 0.54 0.43
EV/Net Sales(x) 1.07 0.97 1.23 1.8 2.91 2.79 1.91 1.56 1.38 2.31 3.24
EV/Core EBITDA(x) 9.2 6.56 8.12 10.1 17.65 20.83 70.87 8.04 5.99 8.91 14.52
Net Sales Growth(%) 10.02 12.42 3.49 15.13 -6.79 -3.3 -12.29 9.71 14.43 71.07 -10.21
EBIT Growth(%) 163.92 74.57 -2.73 54.45 -4.23 -26.97 -114.77 1113.46 44.47 133.43 -21.11
PAT Growth(%) 80.54 142.68 101.69 179.87 -2.97 -41.53 -250.87 221.86 65.2 177.87 -21.93
EPS Growth(%) 80.54 140.66 129.92 160.59 -7.64 -30.34 -195.13 330.53 44.06 103.87 -21.95
Debt/Equity(x) 3.02 2.61 2.37 1.73 0.55 0.48 0.52 0.54 0.39 0.27 0.27
Current Ratio(x) 1.03 0.98 0.98 1.02 1 1.14 1.02 1.17 1.45 1.85 1.84
Quick Ratio(x) 0.58 0.5 0.53 0.58 0.61 0.75 0.67 0.84 0.99 1.35 1.38
Interest Cover(x) 0.74 1.25 1.31 2.39 2.38 1.74 -0.26 2.4 3.51 11.86 8.58
Total Debt/Mcap(x) 3.66 3.02 1.2 0.42 0.15 0.16 0.3 0.45 0.33 0.09 0.09

Themis Medicare Shareholding Pattern

# Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Promoter 67.18 67.18 67.18 67.18 67.18 67.16 67.16 67.16 67.16 67.15
FII 0 0 0 0.02 0.02 0.06 0.04 0.05 0.01 0.03
DII 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Public 32.81 32.81 32.81 32.8 32.79 32.77 32.79 32.78 32.82 32.81
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Company has delivered good profit growth of 44% CAGR over last 5 years
  • Company is almost debt free.

Cons

  • Debtor days have increased from 87.3 to 130.58days.
  • Stock is trading at 5.2 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Themis Medicare News

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares

Please Login!

Click to Login
OR
Get free Account

Error!